Huang S.-T.,Chang Gung Memorial Hospital Linkou |
Huang S.-T.,Chang Gung University |
Jiann B.-P.,National Yang Ming University
International Journal of Impotence Research | Year: 2013
The Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) and its partner version questionnaire were used to assess couples' satisfaction with the use of phosphodiesterase type 5 (PDE5) inhibitors to treat erectile dysfunction (ED) over a 3-month period. Of 161 ED patients, who together with their female partners were invited to answer separate questionnaires at home, 111 patients (68.9%; mean age 61.8 (23-87) years) and female partners (mean age 52.8 (22-77) years) returned completed questionnaires. Patients reported a substantially higher treatment satisfaction score and level of satisfaction with ED treatment than their female partners (P<0.001). Patients with milder severity of ED at baseline and better erectile function after treatment were more likely to be satisfied with the outcome of the treatment. Of the different aspects of satisfaction that patients were asked about, they reported the lowest level of satisfaction about their partners' feeling about continued treatment for ED. Our study shows that more patients than their female partners are more satisfied with medical treatment for ED. To maintain long-term therapy for ED, it is important to include female partners in the assessment and management of the therapy. © 2013 Macmillan Publishers Limited All rights reserved.
Yu C.,Soochow University of China |
Wan W.,Soochow University of China |
Zhang B.,Soochow University of China |
Deng S.,Soochow University of China |
And 2 more authors.
Nuclear Medicine and Biology | Year: 2012
Introduction: P-glycoprotein (P-gp) is a cell-membrane-associated protein that transports a variety of drug substrates. We sought to evaluate the relationship between 2-[ 18F]fluoro-2-deoxy-d-glucose ([ 18F]FDG) and P-gp expression using breast carcinoma Bcap37/multidrug resistant (MDR1) and Bcap37 in vitro and in vivo. Methods: The function of P-gp expressed in Bcap37/MDR1 cells was evaluated using verapamil (VER), a classical inhibitor of P-gp. The accumulation of 99mTc-methoxyisobutylisonitrile ([ 99mTc]MIBI) in vitro was measured. In vivo imaging of severe combined immune deficiency (SCID) mice implanted with Bcap37 and Bcap37/MDR1 cells was performed by scintigraphy and micro-positron emission tomography (PET). Results: The uptake of [ 99mTc]MIBI was 0.62%±0.05% in the Bcap37/MDR1 cells and 2.02%±0.28% in the Bcap37 cells. VER significantly increased the uptake of [ 99mTc]MIBI in the Bcap37/MDR1 cells (1.90%±0.09%) but not in the Bcap37 cells (2.15%±0.27%). In vivo, neither the Bcap37 nor Bcap37/MDR1 tumors grown in the SCID mice could be detected by [ 99mTc]MIBI scintigraphy. Both the Bcap37 and Bcap37/MDR1 tumors were visible by micro-PET. The mean standardized uptake value (SUV) was significantly higher in the Bcap37 tumors (1.00±0.06) than in the Bcap37/MDR1 (0.67±0.11) tumors. VER significantly increased the mean SUV in the Bcap37/MDR1 tumors (1.02±0.16) but not in the Bcap37 tumors (1.09±0.22). Conclusions: [ 18F]FDG combined with VER may be an effective noninvasive method of determining P-gp expression in tumors. © 2012 Elsevier Inc..
Lee C.-H.,Chang Gung Memorial Hospital Linkou |
Lee C.-H.,Chang Gung University |
Chiang C.-L.,Chang Gung University |
Liu S.-J.,Chang Gung University
Separation and Purification Technology | Year: 2013
In this study we developed rhodanine loaded nanofibrous membranes for the removal of heavy metal ions. Rhodanine and polymethylmethacrylate dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) were electrospun into nanofibrous membranes via an electrospinning process. The morphology of as-spun rhodanine/polymethylmethacrylate nanofibers was examined by scanning electron microscopy. The average diameter of electrospun nanofibers ranged from 840 nm to 1440 nm. The adsorption capability of nanofibrous rhodanine/ polymethylmethacrylate membranes was measured and compared with that of bulk rhodanine. The influence of various process conditions on adsorption efficiency was also examined. The experimental results suggested that the electrospun nanofibrous membranes exhibit good Ag (I) and Pb (II) ion uptake capabilities. The metal uptake of nanofibrous membranes increased with the initial metal ion concentrations and decreased with the filtering rate of the solutions. Furthermore, the electrospun membrane could be reused after the recovery process. The empirical results in this study suggested that electrospun rhodanine/polymethylmethacrylate nanofibrous membranes can be a good candidate for the removal of heavy metal ions. © 2013 Elsevier B.V. All rights reserved.
Hsiao C.-C.,Chang Gung University |
Hsiao C.-C.,University of Amsterdam |
Wang W.-C.,Chang Gung University |
Kuo W.-L.,Chang Gung University |
And 4 more authors.
FEBS Journal | Year: 2014
CD97 is a tumor-associated adhesion-class G-protein-coupled receptor involved in modulating cell migration. Adhesion-class G-protein-coupled receptors are characterized by proteolytic cleavage at a G-protein-coupled receptor proteolysis site (GPS) into an N-terminal fragment (NTF) and a C-terminal fragment (CTF), which remain associated noncovalently. The molecular mechanism and the role of GPS proteolysis in CD97-modulated cell migration are not completely understood. We report here that CD97 expression in HT1080 fibrosarcoma cells enhanced tissue inhibitor of metalloproteinase-2 secretion, leading to reduced membrane type 1 matrix metalloproteinase and matrix metalloproteinase 2 activities. This, in turn, impaired cell migration and invasion in vitro and lung macrometastasis in vivo. CD97 expression also upregulated the expression of integrins, promoting cell adhesion. Importantly, these cellular functions absolutely required the presence of both the NTF and the CTF of CD97, confirming functional cooperation between the two receptor subunits. CD97 gene knockdown reversed these phenotypic changes. We conclude that GPS proteolysis and the functional interplay between the NTF and the CTF are indispensible for CD97 to inhibit HT1080 cell migration by suppressing matrix metalloproteinase activity. © 2014 FEBS.
Yu H.-J.,National Taiwan University Hospital |
Lin A.T.-L.,Taipei Veterans General Hospital |
Yang S.S.-D.,Buddhist Tzu Chi General Hospital |
Tsui K.-H.,Chang Gung Memorial Hospital Linkou |
And 5 more authors.
BJU International | Year: 2011
Study Type - Therapy (RCT) Level of Evidence 1b What's known on the subject? and What does the study add? Silodosin administered by 4 mg twice daily is as effective as tamsulosin 0.2 mg daily in treating patients with LUTS associated with BPH. Relative to tamsulosin, silodosin has less cardiovascular side effects as judged by the minimal changes of blood pressure and pulse rats after treatment. OBJECTIVE • To test the hypothesis that the efficacy of silodosin would not be inferior to tamsulosin in treating patients with lower urinary tract symptoms associated with benign prostate hyperplasia (BPH). PATIENTS AND METHODS • At nine medical centres, 209 patients with an International Prostate Symptom Score (IPSS) of ≥13 were randomized to silodosin (4 mg twice daily) or tamsulosin (0.2 mg once daily) for 12 weeks. • The primary efficacy measure was the mean change from baseline to endpoint in IPSS. • The non-inferiority margin of the IPSS change was set at 1.0. • Secondary efficacy measures included change in maximal urinary flow rate (Q max) and health-related quality of life (HRQL) score. RESULTS • Of the 170 (81.3%) patients who completed the study, 86.2% in the silodosin group vs 81.9% in the tamsulosin group achieved a ≥25% decrease in IPSS (P= 0.53). • The mean difference (silodosin minus tamsulosin) in IPSS change from baseline was -0.60 (95% confidence interval -2.15, 0.95), inferring the non-inferiority of silodosin to tamsulosin. • The mean changes in the Q max and HRQL score from baseline were comparable between the groups (both, P > 0.05). Although patients receiving silodosin had a significantly higher incidence of abnormal ejaculation (9.7% vs tamsulosin 1.0%, P= 0.009), only 1.9% discontinued treatment. • Tamsulosin treatment resulted in a significant reduction in mean systolic blood pressure (-4.2 mmHg, within-group P= 0.004) relative to the negligible change of silodosin (-0.1 mmHg, within-group P= 0.96) CONCLUSION • The trial shows the non-inferiority of silodosin 4 mg twice daily to tamsulosin 0.2 mg once daily in patients with symptoms of BPH. © 2011 BJU INTERNATIONAL.